Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 853.00 |
Description | Anti-diabetic drugs of the thiazolidinedione (TZD) structural class as well as α-lipoic acid activate peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor that controls glucose metabolism and lipid homeostasis. CAY10506 is a hybrid lipoic acid-TZD derivative that transactivates human PPARγ with an EC50 value of 10 μM. |
Synonyms | CAY10506 |
Molecular Weight | 454.63 |
Formula | C20H26N2O4S3 |
CAS No. | 292615-75-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 3 mg/mL
DMF: 5 mg/mL
DMSO:PBS(pH 7.2) (1:5): 0.15 mg/mL
DMSO: 5 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CAY10506 292615-75-9 CAY 10506 CAY-10506 inhibitor inhibit